Earned Wealth Advisors LLC Has $1.76 Million Stock Holdings in Eli Lilly and Company $LLY

Earned Wealth Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 16.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,252 shares of the company’s stock after selling 437 shares during the quarter. Earned Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,755,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. Covestor Ltd grew its stake in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after buying an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at $242,000. Finally, Golden State Wealth Management LLC grew its position in shares of Eli Lilly and Company by 9.1% in the first quarter. Golden State Wealth Management LLC now owns 1,019 shares of the company’s stock valued at $842,000 after purchasing an additional 85 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. Berenberg Bank restated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Finally, The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $936.47.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $842.28 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s 50-day simple moving average is $777.69 and its 200-day simple moving average is $770.84. The firm has a market cap of $797.18 billion, a P/E ratio of 55.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 39.22%.

Insider Buying and Selling

In other news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.